Sartor, C; Abbenante, M; Papayannidis, C; Iacobucci, I; Paolini, S; Ottaviani, E; Lonetti, A; Parisi, S; Ferrari, A; Guadagnuolo, V; Testoni, N; Cavo, M; Martinelli, G, NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF A SINGLE CENTRE EXPERIENCE, in: supplement 1, «HAEMATOLOGICA», 2013, vol. 98 no. supplement 1 1-768, pp. 499 - 499 (atti di: 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013) [atti di convegno-abstract]
Sartor C; Abbenante MC; Papayannidis C; Iacobucci I; Paolini S; Ottaviani E; Lonetti A; Parisi S; Ferrari A; Guadagnuolo V; Grilli S; Testoni N; Cavo M; Martinelli G., Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience, in: Cancer Research, American Association for Cancer Research (AACR), «CANCER RESEARCH», 2013, 73(8) Suppl. 1, pp. 1179 - 1179 (atti di: AACR 104th Annual Meeting 2013, WASHINGTON DC, 05 - 10 April 2013) [atti di convegno-abstract]
C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah; and on behalf of the International Myeloma Working Group [;Elena Zamagni;], Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, «LEUKEMIA», 2013, 27, pp. 780 - 791 [articolo]
San Miguel J;Weisel K;Moreau P;Lacy M;Song K;Delforge M;Karlin L;Goldschmidt H;Banos A;Oriol A;Alegre A;Chen C;Cavo M;Garderet L;Ivanova V;Martinez-Lopez J;Belch A;Palumbo A;Schey S;Sonneveld P;Yu X;Sternas L;Jacques C;Zaki M;Dimopoulos M, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial., «THE LANCET ONCOLOGY», 2013, 14, pp. 1055 - 1066 [articolo]
Brioli A;Boyd KD;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ, Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy., «BRITISH JOURNAL OF HAEMATOLOGY», 2013, 161, pp. 291 - 294 [articolo]
Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E., Role of consolidation therapy in transplant eligible multiple myeloma patients., «SEMINARS IN ONCOLOGY», 2013, 40, pp. 610 - 617 [articolo]
Borsi, E; Perrone, G; Terragna, C; Martello, M; Mancini, M; Leo, E; Zamagni, E; Tacchetti, P; Brioli, A; Pantani, L; Zannetti, B; Martinelli, G; Cavo, M, SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma, in: CANCER RESEARCH, 2013, pp. 3415 - 3415 (atti di: 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, APR 06-10, 2013) [atti di convegno-abstract]
Nanni C; Zamagni E; Celli M; Caroli P; Ambrosini V; Tacchetti P; Brioli A; Zannetti B; Pezzi A; Pantani L; Perrone G; Zompatori M; Cavo M; Colletti PM; Rubello D; Fanti S., The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients, «CLINICAL NUCLEAR MEDICINE», 2013, 38, pp. e74 - e79 [articolo]
Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Cristina Papayannidis, Ilaria Iacobucci, Claudia Venturi, Manuela Mancini, Elisa Leo, Hana Klamova, Stefania Paolini, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli, Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy, «BLOOD», 2013, 122, pp. 380 - 380 [abstract]
Soverini S; De Benedittis C; Machova Polakova K; Brouckova A; Horner D; Iacono M; Castagnetti F; Gugliotta G; Palandri F; Papayannidis C; Iacobucci I; Venturi C; Bochicchio MT; Klamova H; Cattina F; Russo D; Bresciani P; Binotto G; Giannini B; Kohlmann A; Haferlach T; Roller A; Rosti G; Cavo M; Baccarani M; Martinelli G., Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain., «BLOOD», 2013, 122, pp. 1634 - 1648 [articolo]
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A., Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide., «BLOOD», 2012, 119, pp. 933 - 939 [articolo]
Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A., Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma., «BLOOD», 2012, 120, pp. 9 - 19 [articolo]
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA; MM-015 Investigators., Continuous lenalidomide treatment for newly diagnosed multiple myeloma., «THE NEW ENGLAND JOURNAL OF MEDICINE», 2012, 366, pp. 1759 - 1789 [articolo]
P. Spinnato; A. Bazzocchi; A. Brioli; C. Nanni; E. Zamagni; U. Albisinni; M. Cavo; S. Fanti; G. Battista; E. Salizzoni, Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease, «EUROPEAN JOURNAL OF RADIOLOGY», 2012, 81, pp. 4013 - 4018 [articolo]
